Aktuellt
SENASTE
Redeye maintains a positive view on LIDDS after the successful completion of phase I safety and tolerability study with NanoZolid combined with docetaxel. The drug candidate shows signs of efficacy and it is on a path to become an important asset for the company. We also welcome the culture and strategy change initiated by the new CEO.
LÄS MER
